Sign in
Taking peopleNo phase

The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.

Key facts

Who runs it
Shanghai HeartEpoch Medical Technology Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
10 people, planned
Started
19 Nov 2025
Expected to end
Nov 2032
Type of study
Interventional
Treatments tested
  • mitral valve replacement
Record updated
6 July 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • ≥ 60 years old
  • severe mitral regurgitation or severe mitral stenosis confirmed by ECHO
  • surgical mitral valve replacement

Who cannot take part

  • History of cardiac surgery or history of cardiac intervention( within 1 year), Concurrent cardiac surgery(excluding tricuspid valve repair surgery or atrial fibrillation ablation) or cardiac interventional procedures
  • Severe macrovascular lesions require surgical treatment
  • There was evidence of acute myocardial infarction within 1 month before the surgery (Q-wave MI or non-Q-wave MI, CK-MB ≥ twice the normal level and/or elevated troponin);
  • here was a history of cerebrovascular events (CVA) within 1 month before the surgery, including ischemic and hemorrhagic strokes, but excluding transient ischemic attacks (TIA)
  • Coronary artery disease that requires revascularization;
  • Patients with active bleeding, bleeding tendencies or those who are unable to receive anticoagulant therapy;
  • Confirmed or suspected diagnosis of infective endocarditis or other active infections
  • There are diseases that significantly affect the evaluation of treatment, such as patients with neurological disorders that affect cognitive abilities, and patients with malignant tumors and an expected lifespan of no more than one year;
  • LVEF < 50%
  • STS ≥8;
  • intracardiac mass, thrombus or neoplasm confirmed by echo
  • A pacemaker need to be implanted
  • Other situations in which patients are not suitable to participate in this trial

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims to evaluate the feasibility and safety of polymer artificial heart valve designed and developed by Shanghai HeartEpoch Medical technology Co. Ltd. for the treatment of the mitral valve diseases.

The group in the trial

  • Polymer Artificial Heart ValveTreatment being tested

    Device: Polymer Artificial Heart Valve Mitral valve replacement

    Treatment: mitral valve replacement

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter Clinical Trial Evaluating the Feasibility and Safety of Polymer Artificial Heart Valve for the Treatment of Mitral Valve Diseases
Criteria questions
Built from NCT07243184, who can take part
Record updated
6 July 2026